Compare MKSI & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MKSI | NBIX |
|---|---|---|
| Founded | 1961 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.4B | 15.5B |
| IPO Year | 1997 | 1996 |
| Metric | MKSI | NBIX |
|---|---|---|
| Price | $281.83 | $145.62 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 28 |
| Target Price | ★ $410.86 | $207.81 |
| AVG Volume (30 Days) | 1.0M | ★ 1.2M |
| Earning Date | 11-04-2026 | 10-27-2026 |
| Dividend Yield | ★ 0.36% | N/A |
| EPS Growth | ★ 55.52 | 41.95 |
| EPS | ★ 3.60 | 3.30 |
| Revenue | ★ $3,931,000,000.00 | $161,626,000.00 |
| Revenue This Year | $29.26 | $36.49 |
| Revenue Next Year | $20.69 | $16.51 |
| P/E Ratio | $75.34 | ★ $42.64 |
| Revenue Growth | 9.62 | ★ 977.51 |
| 52 Week Low | $121.28 | $122.14 |
| 52 Week High | $447.62 | $186.12 |
| Indicator | MKSI | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 59.07 | 45.12 |
| Support Level | $280.83 | $125.85 |
| Resistance Level | $294.05 | $161.41 |
| Average True Range (ATR) | 8.60 | 3.88 |
| MACD | 4.82 | 0.14 |
| Stochastic Oscillator | 95.43 | 43.89 |
MKS Inc delivers foundational technology solutions for leading edge semiconductor manufacturing, electronics and packaging, and specialty industrial applications. The company provides instruments, components, subsystems, systems, process control solutions, and specialty chemicals technology that improve process performance and optimize productivity. Its solutions address challenges of miniaturization and complexity in device manufacturing, enabling increased power, speed, and feature enhancement. MKS Inc operates through three divisions: Vacuum Solutions Division (VSD), Photonics Solutions Division (PSD), and Materials Solutions Division (MSD). The company operates in the United States, which generates maximum revenue, as well as China and other countries.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.